Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount

Bristol Myers Squibb and Pfizer will directly sell their blockbuster blood thinner, Eliquis, to uninsured and underinsured patients at a 40%+ discount, lowering the monthly cost from $606 to $346 by bypassing traditional middlemen. This initiative responds to Trump administration pressure on drug pricing, despite the discounted price remaining significantly higher than typical insured patient out-of-pocket costs or future Medicare-negotiated rates. Leerink Partners analysts do not anticipate this program will create a net pricing headwind for the companies, citing existing substantial rebates offered to pharmacy benefit managers.

Analysis

Bristol Myers Squibb and Pfizer are proactively managing political and regulatory risk by launching a direct-to-patient sales program for their blockbuster drug, Eliquis. This initiative, which bypasses pharmacy benefit managers (PBMs) and insurers, offers a more than 40% discount by reducing the monthly list price from approximately $606 to $346 for uninsured, underinsured, and self-pay patients. The move is a direct response to mounting pressure from the Trump administration on drug pricing and potential tariffs. Despite the significant discount from the list price, the new $346 price point remains substantially higher than the average $38 out-of-pocket cost for commercially insured patients and the $231 per month price negotiated by Medicare under the Inflation Reduction Act, which becomes effective next year. According to Leerink Partners, the financial impact on the companies is expected to be minimal, as the program is unlikely to create a 'net pricing headwind.' This assessment is based on the fact that BMY and PFE already provide substantial rebates to PBMs, and this new channel targets the small fraction of patients (under 10%) not covered by insurance, suggesting a strategic repositioning rather than a material erosion of net revenue.

Key Decisions for Investors

• View this program primarily as a defensive and political risk-mitigation strategy that is unlikely to materially impact near-term Eliquis revenue, given that analysts anticipate no significant net pricing headwind due to existing rebates.
• Monitor the evolving regulatory landscape closely, as this move underscores the industry's sensitivity to both potential Trump-era policies and the ongoing implementation of the Inflation Reduction Act, which remain the key long-term risks to pharmaceutical pricing power.
• Consider this a pilot for a direct-to-consumer model that could disrupt the role of PBMs; its performance may indicate a future strategic shift for BMY, PFE, and the broader industry.